BRPI1016173A2 - processo para a produção de partículas de vetores poliomaviral recombinantes - Google Patents

processo para a produção de partículas de vetores poliomaviral recombinantes

Info

Publication number
BRPI1016173A2
BRPI1016173A2 BRPI1016173-2A BRPI1016173A BRPI1016173A2 BR PI1016173 A2 BRPI1016173 A2 BR PI1016173A2 BR PI1016173 A BRPI1016173 A BR PI1016173A BR PI1016173 A2 BRPI1016173 A2 BR PI1016173A2
Authority
BR
Brazil
Prior art keywords
vector particles
relates
processes
production
viral
Prior art date
Application number
BRPI1016173-2A
Other languages
English (en)
Inventor
Gerhardus De Vries Walter
Original Assignee
Amarna Holding B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarna Holding B.V. filed Critical Amarna Holding B.V.
Publication of BRPI1016173A2 publication Critical patent/BRPI1016173A2/pt
Publication of BRPI1016173B1 publication Critical patent/BRPI1016173B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22051—Methods of production or purification of viral material
    • C12N2710/22052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

processo para a produção de partículas de vetores poliomaviral recombinantes. a presente invenção refere-se a processos aperfeiçoados para a produção de partículas virais, partículas de vetores virais e proteínas recombinantes. em particular, a invenção refere-se a processos aperfeiçoados para a produção de partículas vetores poliomavirais recombinantes e linhas de células de produção de vetor poliomaviral. mais em particular, a invenção refere-se a processos para a produção de partículas vetores poliomavirais de símios tais como partículas vetores virais de vírus símio 40 (sv40). a invenção também se refere a composições compreendendo vetores virais e seus usos e partículas vetores virais para tratamento de distúrbios genéticos, rejeição de transplante, doenças autoimunes, doenças infecciosas, alergias ou câncer. a invenção também se refere a processos para a produção de proteínas recombinantes em células mamíferas e processos para aperfeiçoamento de produção de proteínas recombinantes em células mamíferas.
BRPI1016173-2A 2009-04-22 2010-04-22 Processo para a produção de partículas de vetores poliomaviral recombinantes, e composição BRPI1016173B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09158498.7 2009-04-22
EP09158498A EP2243836A1 (en) 2009-04-22 2009-04-22 Method for the production of recombinant polymavirus vector particles
PCT/EP2010/055330 WO2010122094A1 (en) 2009-04-22 2010-04-22 Method for the production of recombinant polyomaviral vector particles

Publications (2)

Publication Number Publication Date
BRPI1016173A2 true BRPI1016173A2 (pt) 2019-10-01
BRPI1016173B1 BRPI1016173B1 (pt) 2026-02-24

Family

ID=

Also Published As

Publication number Publication date
CA2759596A1 (en) 2010-10-28
US20120040399A1 (en) 2012-02-16
US9587226B2 (en) 2017-03-07
JP5756795B2 (ja) 2015-07-29
MX2011010612A (es) 2012-01-12
EP2243836A1 (en) 2010-10-27
JP2012524531A (ja) 2012-10-18
KR20120006062A (ko) 2012-01-17
AU2010240900A1 (en) 2011-10-20
DK2421982T3 (en) 2015-10-05
EA201101532A1 (ru) 2012-04-30
ES2548990T3 (es) 2015-10-22
KR101813723B1 (ko) 2017-12-29
CN102695800A (zh) 2012-09-26
EA022206B1 (ru) 2015-11-30
AU2010240900B2 (en) 2015-06-11
EP2421982A1 (en) 2012-02-29
EP2421982B1 (en) 2015-07-01
CA2759596C (en) 2017-08-01
WO2010122094A1 (en) 2010-10-28
CN102695800B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
CA2877521C (en) Cells for producing recombinant iduronate-2-sulfatase
MX364690B (es) Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero.
WO2011091350A3 (en) Methods & compositions for improving protein production
SA520411930B1 (ar) وسيلة وطريقة لتحضير الموجهات الفيروسية واستخداماته
WO2011075686A3 (en) Methods & compositions comprising heat shock proteins
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
CA2806858C (en) Reprogramming immortalized b cells
BR112012007854A2 (pt) metodos de produção de glicoproteínas em culturas de células de mamíferos usando glicocorticoides
MY205245A (en) Scalable method for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
MX2018011384A (es) Arn de replicacion en trans.
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
MX2007003906A (es) Metodos y composiciones para mejorar la produccion de proteinas recombinantes.
EA201101532A1 (ru) Способ получения частиц рекомбинантного полиомавирусного вектора
GB0911870D0 (en) Optimised coding sequence and promoter
IN2012DN00801A (pt)
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
BR112015022464A2 (pt) anticorpos anti-cd52, seu método de preparação bem como seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, linhagem celular isolada, e composição
JP2017524366A5 (pt)
BR112016027818A2 (pt) composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b.
MX2015016670A (es) Proceso para preparar apolipoproteina a-i (apo- a-i).
MX2021010776A (es) Proteina recombinante del dominio rbd de la proteina spike del virus sars-cov-2 y metodos para su obtencion.
Lee et al. The improvement of porcine epidemic diarrhea vaccine production through in situ removal of ammonium ions by zeolite
BR112013029902A2 (pt) produção de alta pureza de proteínas de múltiplas subunidades, tal como anticorpos, em micróbios transformados, tal como pichia pastoris

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.